NKGen Biotech Korea엔케이젠바이오텍코리아
182400 · KOSDAQ · ₩182400 · 엔케이젠바이오텍코리아
- Market cap
- ₩265B
- Enterprise value
- ₩264B
- P/E
- —
- P/B
- 40.3×
- Dividend yield
- 0.0%
- ROE
- −60.3%
- Net margin
- −48.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−0.4% from the high
₩3,670Today: ₩3,670 – ₩3,670₩3,685
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD−0.4%
- 1Y−0.4%
- Volume today
- —
- Traded today
- —
- Listed shares
- 72,342,431
- EPS (12 months)
- −₩55
- Earnings yield −1.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
NKGen Biotech Korea stock overview
NKGen Biotech Korea (엔케이젠바이오텍코리아, KRX: 182400) is listed on KOSDAQ, in the Biotech & Pharma sector. Korean company that emerged from court-supervised rehabilitation in September 2025 and was renamed NKGen Biotech Korea, with NKGen Biotech, Inc. Its shares closed at ₩3,670 on Oct 30, 2026, unchanged on the day, giving it a market value of ₩265B.
Key facts
- Market cap
- ₩265B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 30, 2026
- Main business
- Korean company that emerged from court-supervised rehabilitation in September 2025 and was renamed NKGen Biotech Korea, with NKGen Biotech, Inc.
Quick answers about NKGen Biotech Korea
- What does NKGen Biotech Korea do?
- Korean company that emerged from court-supervised rehabilitation in September 2025 and was renamed NKGen Biotech Korea, with NKGen Biotech, Inc. as the designated acquirer. It develops NK cell-based immunotherapies such as the SuperNK platform for hard-to-treat diseases including cancer and Alzheimer's disease, and sells the NK Vue Kit blood test that measures NK cell activity, the NK365 immune health supplement, and research reagents such as recombinant proteins and monoclonal antibodies, with most reagent sales exported to customers abroad.
- What is the market cap of NKGen Biotech Korea?
- The market capitalisation of NKGen Biotech Korea was ₩265B at the close on Oct 30, 2026.
- Who are the largest shareholders of NKGen Biotech Korea?
- According to the latest official filings, the largest reported holders are NKGenBiotech,Inc. (64.14%, as of Apr 22, 2026); Meritz Securities (4.59%, as of Jul 11, 2025); Park Geun-ho (2.07%, as of Jul 10, 2025).
- When is the next earnings report from NKGen Biotech Korea?
- Korean companies rarely announce results dates in advance. Based on when NKGen Biotech Korea filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Korean company that emerged from court-supervised rehabilitation in September 2025 and was renamed NKGen Biotech Korea, with NKGen Biotech, Inc. as the designated acquirer. It develops NK cell-based immunotherapies such as the SuperNK platform for hard-to-treat diseases including cancer and Alzheimer's disease, and sells the NK Vue Kit blood test that measures NK cell activity, the NK365 immune health supplement, and research reagents such as recombinant proteins and monoclonal antibodies, with most reagent sales exported to customers abroad.
Written by AI from the company's latest annual report.
- Korean name
- 엔케이젠바이오텍코리아
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김용만
- Founded
- Jan 2002
- Listed
- Oct 2015
- Listed shares
- 72,342,431
- Fiscal year ends
- Month 12
- Website
- www.nkmax.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Amended: Half-year report (Jun 2026)Sep 30, 2026
- Added attachment: Half-year report (Jun 2026)Aug 13, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Amended: Change of largest shareholderApr 22, 2026
- 5%+ holding reportApr 22, 2026
Titles in Korean until English translations are added.
Also known as: NKGen Biotech Korea / 엔케이젠바이오텍코리아 / 182400 / KRX:182400
Source: KRX statistical information